851 results about "Esophageal cancer" patented technology

A capsule is coupled to a tether that is manipulated to position the capsule and a scanner included within the capsule at a desired location within a lumen in a patient's body. Images produced by the scanner can be used to detect Barrett's Esophagus (BE) and early (asymptomatic) esophageal cancer after the capsule is swallowed and positioned with the tether to enable the scanner in the capsule to scan a region of the esophagus above the stomach to detect a characteristic dark pink color indicative of BE. The scanner moves in a desired pattern to illuminate a portion of the inner surface. Light from the inner surface is then received by detectors in the capsule, or conveyed externally through a waveguide to external detectors. Electrical signals are applied to energize an actuator that moves the scanner. The capsule can also be used for diagnostic and / or therapeutic purposes in other lumens.

A capsule is coupled to a tether that is manipulated to position the capsule and a scanner included within the capsule at a desired location within a lumen in a patient's body. Images produced by the scanner can be used to detect Barrett's Esophagus (BE) and early (asymptomatic) esophageal cancer after the capsule is swallowed and positioned with the tether to enable the scanner in the capsule to scan a region of the esophagus above the stomach to detect a characteristic dark pink color indicative of BE. The scanner moves in a desired pattern to illuminate a portion of the inner surface. Light from the inner surface is then received by detectors in the capsule, or conveyed externally through a waveguide to external detectors. Electrical signals are applied to energize an actuator that moves the scanner. The capsule can also be used for diagnostic and / or therapeutic purposes in other lumens.

A method for treating Barrett's esophagus and esophageal cancer by using non-thermal electroporation energy to ablate diseased portions of the esophagus which, in effect, prevents stomach acids and other fluids from entering the esophagus thereby alleviating continued deterioration of the esophagus and allows the columnar cells in the lining of the esophagus to assume their normal physical characteristics and functions and.

The present invention relates to pharmaceutical compositions and dietary supplement comprising yeast cells that can produce a healthful benefit in a subject inflicted with esophageal cancer. The biological compositions can be used to retard the growth of esophageal cancer cells and / or prolonging the time of survival of the subject. The invention also relates to methods for manufacturing the biological compositions.

The invention discloses a traditional Chinese medicine preparation for treating cancer, which is prepared by 103 types of bulk drugs such as solidago decurrens, Chinese sage herb, hypericum japonicumand the like. A preparation method of the traditional Chinese medicine preparation comprises the following steps: preparing the bulk drugs into water extract by a conventional method; using the prepared water extract for preparing oral solution by a traditional method; drying the obtained water extraction, then conducting grinding and sieving; taking the throughs for extracting powder, and using the extracted powder for preparing tablets, granules, electuaries or capsules by a traditional method. The preparation method also can be as follows: sieving out the dust of the bulk drugs, conductinggrinding and sieving, taking the throughs, conducting disinfection and sterilization to obtain raw powder, and using the raw powder for preparing tablets, granules, electuaries or capsules by a traditional method. With drugs mixed rationally, the traditional Chinese medicine preparation addresses both the symptoms and root causes of cancer. The bulk drugs are frequently-used common Chinese drugs,have low preparation cost and small side effect, and can effectively enhance own immunity, attack pathogen while do not damage body. The traditional Chinese medicine preparation can cure various typesof cancer, particularly lung cancer, stomach cancer, liver cancer, esophageal cancer, pancreatic cancer, cervical cancer and breast cancer.

A highly purified and heat stable cross-linked nonpolymeric tetrameric hemoglobin suitable for use in mammals without causing renal injury and vasoconstriction is provided. A high temperature and short time (HTST) heat processing step is performed to remove undesired dimeric form of hemoglobin, uncross-linked tetrameric hemoglobin, and plasma protein impurities effectively. Addition of N-acetyl cysteine after heat treatment and optionally before heat treatment maintains a low level of met-hemoglobin. The heat stable cross-linked tetrameric hemoglobin can improve and prolong oxygenation in normal and hypoxic tissue. In another aspect, the product is used in the treatment of various types of cancer such as leukemia, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal carcinoma and esophageal cancer. Another application is heart preservation in situations where there is a lack of oxygen supply in vivo, such as in heart transplant or oxygen-deprived heart.

A method of treating cancer by introducing heat into cancerous tissue and delivering a liposome containing an active agent or a thermo-activated drug, gene or virus to said tissue. The heat delivered is sufficient to release the active agent or activate the thermo-activated drug, gene or virus. The cancer can be esophageal cancer. The liposome containing an active agent or a thermo-activated drug, gene or virus can be a thermosensitive liposome. The active agent can be an anti-neoplastic agent, for example doxorubicin.

Provided is pyrazole derivatives as a TNIK (Traf2- and NCK-interacting kinase), IKKε (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the pyrazole derivative according to the present invention effectively inhibits TNIK, IKKε and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

The present invention relates, in part, to the discovery that human FGF19 is amplified in a number of cancers, including liver and esophageal cancers, and that this amplification correlates with over-expression of this gene. In some aspects, the invention provides methods and kits for diagnosing a patient having or at risk for developing cancer, such as liver or esophageal cancer. The invention in other aspects provides methods for selecting a treatment for a patient having cancer. In other aspects, the invention relates to methods for treating cancer using an FGF19 inhibitor.

The invention relates to a nanocomposite temperature-sensitive gel and a preparation method and an application thereof. The preparation method comprises the following steps of: coating antitumor active substances with a high molecular polymer serving as a carrier material to obtain nanoparticles; and adding a temperature-sensitive high molecular material to obtain the nanocomposite temperature-sensitive gel. The preparation method disclosed by the invention is simple and convenient, is suitable for large-scale production, and is particularly suitable for preparing medicaments or diagnostic reagents having the characteristics of long cycle, biodegradability, slow release, passive targeting, active targeting, active substance conveying function and tumor resistance. An antitumor medicament prepared with the method disclosed by the invention is suitable for ways such as intravenous injection, intramuscular injection, hypodermic injection, intradermal injection, intratumor injection, tumor-side injection, oral administration or transdermal medicament delivery and the like, is applied to treatment and diagnosis of pancreatic cancer, liver cancer, lung cancer, gastric cancer, colorectal cancer, esophageal cancer, prostatic cancer, uterine cancer and ovarian cancer, and has a good application prospect.

The invention relates to the isolation of a nucleic acid molecule which encodes an esophageal cancer associated antigen. Also a part of the invention is the antigen itself, and the uses of the nucleic acid molecule and the antigen.

Pharmaceutical compositions and methods for treating cancer using CD44 antagonists are disclosed. In certain aspects, these pharmaceutical compositions and methods include treating a mammal having a cancer, such as glioma, colon cancer, breast cancer, prostate cancer, ovarian cancer, lung cancer, renal cell carcinoma, gastric cancer, esophageal cancer, head cancer, neck cancer, pancreatic cancer, or melanoma, with a CD44 fusion protein. These CD44 fusion proteins include CD44-Fc fusions and can be used to detect hyaluronan.

The invention provides novel compositions, methods and uses, for the diagnosis, prognosis, prediction, prevention and aid in treatment of malignant neoplasia such as breast cancer, ovarian cancer, gastric cancer, colon cancer, esophageal cancer, mesenchymal cancer, bladder cancer or non-small cell lung cancer. Genes that are chromosomally amplified in breast tissue of breast cancer patients are disclosed. Further disclosed are chromosomally amplified genes and non-amplified genes that correlate to Taxane resistance, Taxane benefit or adverse Taxane reaction, which can be used as an aid to make therapy dicisions.

The invention discloses a male multi-tumor marker detection protein chip and a kit thereof. The chip comprises a substrate, protein markers distributed in an array type and point coatings of contrasts, wherein the substrate is a glass substrate or a film substrate; and the tumor markers and the point coatings of the contrasts are seven protein markers of AFP, CEA, NSE, CYFRA21-1, CA19-9, tPSA and SCC-ag, a positive contrast and a negative contrast which are uniformly distributed and latticed on the substrate. A reaction result of various indexes can be obtained only through one reaction by utilizing the protein chip, and the following tumors can be simultaneously screened: primary liver cancer, prostatic cancer, pancreatic cancer, lung cancer, esophageal cancer, gastric cancer and colorectal cancer. The invention is particularly suitable for the general examination of malignant tumors of male asymptomatic groups and high risk groups.

Probe sets and methods of using probes and probe sets for selectively detecting high grade dysplasia and esophageal adenocarcinoma or low grade dysplasia from biologic samples are described. Methods of the invention include contacting a biological sample obtained from a subject with a set of chromosomal probes to selectively detect an esophageal carcinoma or precursor lesion in the sample, if any, under conditions for specifically hybridizing the probes to their nucleic targets present in the sample. The presence or absence of high grade dysplasia and esophageal adenocarcinoma or low grade dysplasia is thereafter specifically determined from the hybridization pattern detected for the set of chromosomal probes to the biological sample.

Objective methods for diagnosing a predisposition to developing cancer, particularly bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer, are described herein. In one embodiment, the diagnostic method involves determining an expression level of PRMT1 gene. The present invention further provides methods of screening for therapeutic agents useful in the treatment of PRMT1 associated disease, such as a cancer, e.g. bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer. The present invention further provides methods of inhibiting the cell growth and treating or alleviating symptoms of PRMT1 associated diseases. The present invention also features products, including double-stranded molecules and vectors encoding thereof as well as to compositions comprising them.

The present invention generally regards gene expression profiling of esophageal cancers, including localized esophageal cancers. In particular, gene expression for a particular group of genes identifies individuals that are either going to be responsive to cancer therapy, for example chemotherapy and / or radiation, or that are not going to be responsive to cancer therapy. Exemplary genes having such expression profiles include, for example, PERP, S100A2, and SPRR3.

The invention discloses an esophageal cancer pathological image automatic discrimination device based on a convolution neural network and a discrimination method thereof. The device comprises an imageacquisition module, an image processing module, a data storage module, a migration learning module, a network training module and a discrimination module. The screening method of the invention comprises the following steps: 1, an image acquisition module collects pathological images and constructs an image database of pathological slices of esophageal cancer; 2, each pathological image database is expanded through an image processing module; 3, the expanded pre-training network pathological image data set is used to complete the migration learning; 4. on the basis of the acquired convolutional neural network structure, the network is trained with the expanded pathological image data set of esophageal cancer and the weights are fine-tuned to get the discriminant network model, and the intelligent discriminant is realized with the discriminant module. The invention overcomes the over-fitting problem in the depth learning process caused by the labeled esophageal cancer pathological imagedata set as a training sample due to the lack of large-scale disclosure, and improves the recognition rate.

The invention relates to novel anti-tumor application of an alkaloid compound penicillium enol A1 from penicillium citrinum. The penicillium citrinum IBPT-5 is collected in the China Center for Type Culture Collection (CCTCC), which is located in Wuhan University and has the collection number of CCTCC NO:M2013713, on December 25, 2013. Experiments prove that the compound has better anti-tumor activity on various tumor cells, and can be used for preparing cell proliferation inhibition medicines or anti-tumor medicines for anti-tumor study, wherein tumor cells comprise human colon cancer cells SW620, human hepatoma cells Huh7, human gastric carcinoma cells BGC-823, human colon cancer cells SW480, human esophageal squamous carcinoma cells KYSE450, human esophageal cancer cells EC9706, human highly metastatic lung carcinoma cells 95-D, human hepatoma cells PLC and human gastric carcinoma cells HGC-27.

The invention belongs to the technical field of tumor medicine, and particularly discloses an autoantibody joint detection ELISA kit for screening early esophageal cancer. The kit comprises a solid-phase carrier and tumor-associated antigens coated on the solid-phase carrier, wherein the tumor-associated antigens are EYA4, ABL1, ATF2, CD38, NOTCH1, ZBTB20, BCL2L1 and P53. Furthermore, the kit alsocomprises a sample diluent, a second antibody, a second antibody diluent, positive control serum, negative control serum, a color developing solution, a stop solution and a washing solution. The ELISA kit provided by the invention can effectively detect esophageal cancer, especially early esophageal cancer, has the detection sensitivity of 94% and the specificity of 79%, can be used for large-scale screening of asymptomatic people in high-incidence areas of esophageal cancer, and is beneficial to screening and early discovery of asymptomatic high-risk population.

This invention relates to a composition, kit, or DNA chip comprising polynucleotides and antibodies as probes for detecting, determining, or predicting the presence or metastasis of esophageal cancer, and to a method for detecting, determining, or predicting the presence or metastasis of esophageal cancer using the same.

Pharmaceutical compositions are provided that are useful in treating or preventing neoplastic disease, such as cancer. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of one or more genes related to the cancer. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of cancer. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl), and the cancer is esophageal cancer, hepatocellular carcinoma, colon cancer, prostate cancer, lung cancer, gastric carcinoma, renal cell carcinoma, bone cancer, breast cancer, cervical cancer, brain cancer, or a cancer associated with the tumor suppressor gene p53.

The invention discloses an esophageal cancer pathological image processing method based on depth learning, which comprises the following steps: a) pathological slice scanning; B) Encircling the epithelial region type, encircling the normal region of the epithelial region, the low-grade and high-grade precancerous lesion region; (c) image preprocess to obtain small epithelial images; (d) divide each epithelial small image into n image blocks along its longitudinal direction by a convolution neural network, and carry out feature extraction on each image block; E) a long-term and short-term memory network LSTM for acquiring feature vectors of small epithelial images; F) Classifier classification; G) Modeling and tuning, h) Accuracy calculation. The esophageal cancer pathological image processing method of the invention After processing by CNN, LSTM network and classifier, the probability of each epithelial small image being normal, low-grade and high-grade precancerous lesions is obtained, which provides an effective digital image processing method for the scientific utilization of pathological esophageal cancer slices. The method has remarkable beneficial effect and is suitable for application and popularization.

The invention relates to novel anti-tumor application of an alkaloid compound penicillium enol B1 from penicillium citrinum. The penicillium citrinum IBPT-5 is collected in the China Center for Type Culture Collection (CCTCC), which is located in Wuhan University and has the collection number of CCTCC NO:M2013713, on December 25, 2013. The compound has good anti-tumor activity to various tumor cells, and can be used for preparing cell proliferation inhibition medicines or anti-tumor medicines for anti-tumor study, wherein tumor cells comprise human colon cancer cells SW620, human hepatoma cells Huh7, human gastric carcinoma cells SGC-7901, human gastric carcinoma cells BGC-823, human colon cancer cells SW480, human esophageal cancer cells EC9706, human highly metastatic lung carcinoma cells 95-D, human hepatoma cells PLC, human gastric carcinoma cells HGC-27 and human lymphoma cells RAJI.

The invention relates to a medicament-tumor number 1 capable of killing cancer cells and curing various tumors and cancers and leukemia. The medicament comprises glossy ganoderma, ginseng, herba epimedii, astragalus membranaceus, giant knotweed rhizome, Chinese caterpillar fungus, heartleaf houttuynia herb and liquorice root. The medicament capable of killing cancer cells and curing various tumors and cancers and leukemia is prepared by pure traditional Chinese medicine, is good in treatment effects, less in side effects, short in treatment course and the like, is rapid in effect and high in cure rate, has effects of killing cancer cells and improving human body immunity, has functions of prolonging life and anti-aging and is capable of curing leukemia and various tumors and cancers, such as leukemia, bone cancer, lymphoma, intestinal cancer, liver cancer, renal carcinoma, gastric cancer, pelvic cancer, uterine cancer, cervical cancer, bladder cancer, prostatic cancer, pancreatic cancer, lung cancer, brain cancer, neuroendocrine tumor, mammary cancer and esophageal cancer.

The present invention provides a combination therapy for effectively treating and / or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the human fibroblast activation protein (FAP / seprase) as a universal marker of different cancer types. Seprase aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., esophagus, head and neck cancer, stomach cancer, bile duct cancer, pancreas cancer, kidney cancer, cervix cancer, ovary cancer, breast cancer, bladder cancer, endometrium cancer or prostate cancer. Furthermore, it especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring seprase in said sample. Measurement of seprase can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and / or brain tumor.

The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast Cancer, lung Cancer, gastric Cancer, ovarian Cancer, hepatocellular Cancer, colon Cancer, pancreatic Cancer, esophageal Cancer, head & neck Cancer, kidney Cancer, in particular renal cell Carcinoma, prostate Cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid Cancer, and the metastatic forms thereof. In one embodiment, the rumor disease is metastatic cancer in the lung.

The invention relates to the preparing method and application of the total triterpene extracts from American solidago decurense. The total triterpene glycosides in the total triterpene extracts include Solidago decurense saponin 1,2,3 and 4, which can prevent and / or treat esophageal cancer, senile dementia, respiratory tract disease caused by different kinds of inflammation such as laryngopharyngitis and tracheitis. The diseases mentioned has been the main pathogeny that influences the quality of human life. The preparing technology of the extract is very simple, the extracting efficiency is very high; the extracts have strong pharmacologic action, stable quality and controllable quality; it's safe with less toxicity. The American Solidago decurense has damaged Chinese natural resources and ecological environment seriously as foreign invasive plant, it has been removed as weeds in many places. The invention can change waste into treasure while providing a new medicine source for preventing, diagnosing, detecting, protecting, treating and researching the mentioned diseases.